9 completed, 5 unknown, 3 recruiting, 1 terminated. 18 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 9, Unknown 5, Recruiting 3, Terminated 1 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
Follow Dapagliflozin 10mg Tab: new trials by email Literature Review of Dapagliflozin 10mg Tab trials Research Report on Dapagliflozin 10mg Tab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome Dapagliflozin 10mg Tab, Placebo - Heart Failure, Acute Kidney Injury | Phase 2 | Recruiting | Yale University | 130 | 2026-03-05 | 2026-03-13 |
| Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity Dapagliflozin 10mg Tab - Doxorubicin Induced Cardiomyopathy, Breast Cancer | Phase 2 | Recruiting | Tanta University | 46 | 2024-10-31 | 2026-04-17 |
| Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients Dapagliflozin 10mg Tab, lifestyle interventions - Prediabetic State, Impaired Fasting Glucose | Phase 2 | Unknown | Yangjin | 120 | 2023-12-20 | 2023-07-25 |
| Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity Dapagliflozin 10mg Tab - Breast Cancer | Phase 2 | Unknown | Fondazione IRCCS Policlinico San Matteo di Pavia | 316 | 2023-10-19 | 2024-04-02 |
| Dapagliflozin in Patients With Ulcerative Colitis Mesalamine, Dapagliflozin 10mg Tab - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Mostafa Bahaa | 60 | 2023-08-20 | 2026-09-21 |
| Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients Dapagliflozin 10mg Tab, Placebo - Fabry Disease | Phase 2 | Unknown | Albina Nowak, MD | 46 | 2023-08-01 | 2023-02-02 |
| A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease. Dapagliflozin 10mg Tab, Balcinrenone 50mg Capsule, Balcinrenone 100mg Capsule - Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis | Phase 2 | Completed | Klinikum Nürnberg | 103 | 2023-07-13 | 2026-04-27 |
| Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders Fluoxetine 20 mg, Dapagliflozin 10mg Tab, Atorvastatin 80mg - Depressive Disorder | Phase 2 | Completed | Tanta University | 75 | 2023-06-06 | 2026-10-30 |
| SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease Dapagliflozin 10mg Tab, Standard maintenance therapy - Lupus Nephritis, Chronic Kidney Diseases | Phase 2 | Recruiting | The University of Hong Kong | 150 | 2023-01-04 | 2024-12-16 |
| Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC) Dapagliflozin 10Mg Tab, Placebo, impedance cardiography - Renal Insufficiency, Chronic | Phase 2 | Completed | University Hospital, Rouen | 32 | 2022-10-18 | 2026-02-06 |
| Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis Dapagliflozin 10Mg Tab, Pioglitazone 30 mg - Non-alcoholic Steatohepatitis | Phase 2 | Completed | Cairo University | 100 | 2022-08-01 | 2024-09-19 |
| Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF) Dapagliflozin 10mg Tab, Placebo - Acute Heart Failure | Phase 2 / Phase 3 | Completed | Mansoura University | 87 | 2022-04-25 | 2023-08-04 |
| TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension Dapagliflozin 10Mg Tab, Placebo - Albuminuria | Phase 2 | Terminated | University Medical Center Groningen | 9 | 2022-02-03 | 2024-04-17 |
| Dapagliflozin in Non-diabetic Stage IV CKD Dapagliflozin 10Mg Tab, Placebo - Chronic Kidney Diseases | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 32 | 2021-11-08 | 2024-05-10 |
| Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure Dapagliflozin 10Mg Tab, Placebo - HFrEF | Phase 2 | Completed | University of Pennsylvania | 3 | 2021-10-22 | 2023-12-12 |
| Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer Dapagliflozin 10Mg Tab - Metastatic Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Unknown | Saint Luke's Health System | 25 | 2021-08-25 | 2021-10-19 |
| GLUcose Transport and REnalPROtection in Chronic Kidney Disease Dapagliflozin 10mg Tab, Placebo - Chronic Kidney Disease, Diabetes Mellitus, Type 2 | Phase 2 / Phase 3 | Completed | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | 34 | 2021-04-13 | 2025-03-28 |
| Dapagliflozin Effect in Cognitive Impairment in Stroke Trial Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant - Stroke, Ischemic, Mild Cognitive Impairment | Phase 2 / Phase 3 | Unknown | Jaime Daniel Mondragon | 270 | 2020-08-01 | 2022-10-04 |
Renal Insufficiency, Chronic (5) · Breast Neoplasms (3) · Acute Kidney Injury (1) · Albuminuria (1) · Cardiotoxicity (1) · Cognitive Dysfunction (1) · Dementia, Vascular (1) · Depressive Disorder (1) · Diabetes Mellitus, Type 2 (1) · Fabry Disease (1) · Fatty Liver (1) · Glucose Intolerance (1) · Heart Failure (1) · Hypertension (1) · Inflammatory Bowel Diseases (1)
Tanta University (2) · Albina Nowak, MD (1) · Cairo University (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (1) · Jaime Daniel Mondragon (1) · Klinikum Nürnberg (1) · Mansoura University (1) · Mario Negri Institute for Pharmacological Research (1) · Mostafa Bahaa (1) · Saint Luke's Health System (1) · The University of Hong Kong (1) · University Hospital, Rouen (1) · University Medical Center Groningen (1) · University of Pennsylvania (1)
Egypt (5) · Italy (3) · United States (3) · France (2) · China (1) · Germany (1) · Hong Kong (1) · Mexico (1) · Netherlands (1)
Abinet Aklilu, MD (1) · Adriana Marton, MD (1) · Desmond Yap, MD (HK) (1) · Dominique Guerrot, MD, PhD (1) · Giuseppe Remuzzi, MD (1) · Jeremy Bellien, PharmD, PhD (1) · Jin Yang, doctorate (1) · Mohamed El-Husseiny Shams, Proffesor (1) · Moheb Magdy Mouris, MD (1) · Nirmeen A. Sabry (1) · Noha Mansour, PhD (1) · Sandy E Rezkallah, bachelor (1)
PMID 20204386, PMID 23040716, PMID 28095900, PMID 28950419, PMID 29016744, PMID 29371333, PMID 29446769, PMID 29573529, PMID 31236801, PMID 31248555, PMID 31535829, PMID 32115470, PMID 32144994, PMID 32178931, PMID 32317958, PMID 32352644, PMID 32559474, PMID 32854852, PMID 33030307, PMID 33282811, PMID 33894597, PMID 34813630, PMID 37923161, PMID 38334499, PMID 38494571, PMID 38855751, PMID 39884573, PMID 40890873, PMID 41223002, PMID 41366613
K23DK142042 (1)